Statement re Delisting

RNS Number:5340O
Arana Therapeutics Limited
22 February 2008


                           Arana Therapeutics Limited

On 11 January 2008, Arana Therapeutics Limited, (AIM: AAHx ASX: AAH) (the
"Company"), the Australian biopharmaceutical company that uses superior
technology to develop next generation drugs that will improve the lives of
patients with inflammatory diseases and cancer, announced resolutions
proposed in respect of its forthcoming annual general meeting ("AGM"), including
the proposed resolution that the listing of the Company's ordinary shares on the
AiM market of the London Stock Exchange be cancelled ("Cancellation").   The
explanatory notes in respect of this resolution stated that such cancellation
will occur no earlier than 5 days after the AGM and is expected to be on or
around 22 February 2008.


At the AGM of the Company dated 14 February 2008 the members of the Company
passed a resolution approving the Cancellation.


The Company today announces that the expected date of Cancellation will now be
on or before 16th May 2008. The actual date will be the earlier of (i) 16 May
2008 and (ii) on or around the date 20 business days after the date when all
holders of depositary interests representing ordinary shares of the Company
("DIs" and "DI Holders") have transferred their holding of ordinary shares of
the Company to the Australian register of the Company's members.


The reason for the Cancellation being later than originally expected is to allow
DI Holders to transfer their holding of ordinary shares of the Company to the
Australian register of the Company's members prior to such transfer occurring
automatically on the termination of the deed constituting the DIs (which will
occur on 16 May 2008, if it has not occurred earlier by reason of all DI Holders
having so transferred their holdings prior to that date).


For further information, please contact:

Arana Therapeutics Limited
Dr John Chiplin, Chief Executive Officer                      [phone]                                        
                                   
Niall Henderson, Chief Financial Officer                      [phone]    
                                                                            

Buchanan Communication
Lisa Baderoon/Rebecca Skye Dietrich                          [phone]
                                                                            

Nomura Code Securities
Charles Walker                                               [phone]
                                                                            




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
STRTTMFTMMATMJP